In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...